Bayer’s Lotrimin and Tinactin antifungal sprays are common over-the-counter treatments for conditions like athlete’s foot and ringworm, and consumers generally expect these products to be safe and reliably manufactured. In October 2021, Bayer issued a recall covering certain aerosol antifungal spray lots sold between September 2018 and October 2021, raising concerns that some recalled products might not meet quality standards for medicines applied directly to the skin. Recalls like this matter because these items are used without a prescription, often repeatedly, and are regulated as OTC drugs—meaning they’re expected to comply with FDA requirements such as current Good Manufacturing Practices (cGMP) for consistent quality and proper controls during production. The class action settlement—reported as a $7 million fund—was filed to resolve claims that consumers paid for recalled Lotrimin or Tinactin spray products that allegedly should not have been sold or did not deliver the expected value due to the recall-related issues. Its significance is less about personal injury and more about consumer protection and refund-style relief: it offers a streamlined way for eligible purchasers to seek compensation (with the settlement site indicating no proof of purchase required) rather than pursuing individual small claims. More broadly, the case fits a familiar pattern in the OTC and personal-care industries, where recalls or contamination/quality allegations can trigger “economic loss” class actions seeking reimbursement, and it underscores how tightly regulated manufacturing and quality controls are central to maintaining trust in mass-market healthcare products.